Zydus receives tentative approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
Sirolimus Tablets had annual sales of USD 69 million in the United States (IQVIA MAT Dec. 2022)
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
Themis will market this drug with the brand name REMITHEM.
USFDA has issued an Establishment Inspection Report (EIR) for Piramal Pharma Limited manufacturing facility located at Lexington (Kentucky, USA) and the inspection has now been successfully closed by the USFDA
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
Subscribe To Our Newsletter & Stay Updated